Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518627 | 1.00 | HSD17B10 (0.60) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL452351 | 0.85 | ALDH1A1 (0.60) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL29403247 | 0.85 | ALDH1A1 (0.60) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL5082000 | 0.84 | HSD17B10 (0.58) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL2025933 | 0.84 | HSD17B10 (0.58) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL7830990 | 0.84 | HSD17B10 (0.58) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL7830991 | 0.82 | HSD17B10 (0.56) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL28240861 | 0.82 | HSD17B10 (0.56) | HSD17B10HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL29430338 | 0.81 | ALDH1A1 (0.56) | HSD17B10ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL17259 | 0.81 | ALDH1A1 (0.56) | HSD17B10ALDH1A1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109516987-B | Preparation method of avibactam intermediate | 江西富祥药业股份有限公司 | 2020-07-24 | — | — | CN | claimed |
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2024246837-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-117402124-A | Aryl sulfonamide compound and anti-influenza application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-16 | — | — | CN | disclosed |
| CN-114957053-B | Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2023-12-22 | — | — | CN | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4164622-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | Icahn School of Medicine at Mount Sinai (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-114957053-A | Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| US-7635711-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1836166-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1836166-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060189646-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006071609-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-0384276-B1 | Water soluble azo compounds, method for their preparation and their use as dyestuffs | HOECHST AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0384276-A1 | Water soluble azo compounds, method for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-29 | — | — | EP | disclosed |
| US-4008208-A | Compositions having inhibited ability to promote platelet aggregation or fibrin clot formation | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3975371-A | Aromatic azo sulfonylnitrene compounds | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3954583-A | Photochemical process | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | HSD17B10 1548/4885HSD11B1 373/4885ALDH1A1 2654/4885 |
| US-20060189646-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HSD17B10 1052/4885HSD11B1 35/4885ALDH1A1 4020/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | HSD17B10 2614/4885HSD11B1 2114/4885ALDH1A1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.